| Nov 1 |
Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
|
| Nov 1 |
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
|
| Nov 1 |
Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
|
| Nov 1 |
Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
|
| Nov 1 |
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
|
| Nov 1 |
Novo Nordisk posts Phase 3 win for obesity drug in MASH
|
| Nov 1 |
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
|
| Nov 1 |
Novo, with new results, to seek approval for obesity drug in MASH
|
| Oct 31 |
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
|
| Oct 30 |
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
|
